TY  - JOUR
TI  - Dexmedetomidine for sedation and correction of psychoemotional disorders in critically ill patients with COVID-19
SN  - 2251-9939
IS  - 05
AV  - public
N2  - Aim. The objective of this study was to evaluate sedation therapy effectiveness in critically ill patients with severe COVID-19 who received dexmedetomidine compared to propofol. Methods. The research was done in a prospective single center to a cohort study of critically ill 333 adult patients with COVID-19 and psychoemotional disorders (depression, anxiety and posttraumatic stress disorder) admitted in the ICU of the Republican Specialized Hospital for COVID-19 in Uzbekistan. Patients were non-invasive ventilated more than 24 hours and received intravenous sedation with dexmedetomidine or propofol. Results. The risk of progression of the pathological process decreased from 47.6% to 21.8% and, accordingly, the proportion of patients with stabilization and improvement of their condition increased from 52.4% to 79.4% (p<0.001). The possibilities of non-invasive respiratory support were expanded with a reduction in the frequency of tracheal intubations from 17.3% to 7.3% (p<0.001), the duration of ICU stay was from 12.6±0.8 to 9.4±0.6 days, and the duration of respiratory therapy was from 8.4±0.5 to 5.2±0.4 days. In particular, there was an improvement in oxygen saturation (SpO2) recovery after one day of intensive therapy from 86.6±0.2% to 92.2±0.3% with non-invasive ventilation and a higher oxygenation index (2.3 in the dexmedetomidine group versus 1.6 in the propofol group, p=0.032) during the period of sedation withdrawal. Conclusion. In the presence of severe psychoemotional disorders, the effectiveness of etiotropic and pathogenetic treatment protocols of COVID-19 directly depends on the proper sedation regimen. In this aspect, dexmedetomidine provides adequate and safe respiratory support with an improvement in external respiration, blood gas composition and a minimal negative hemodynamic effect.
KW  - COVID-19
KW  -   Intensive care unit
KW  -  Depression
KW  -  Anxiety
KW  -  Posttraumatic stress Disorder
KW  -  Sedation
KW  -  Dexmedetomidine
KW  -  Comparison study
SP  - 80
EP  - 87
UR  - https://jlsb.science-line.com/attachments/article/87/JLSB%2011(5)%2080-87,%202021-Dexmedetomidine%20for%20psychoemotional%20disorders%20in%20COVID-19%20patients.pdf
PB  - Scienceline Publications, Ltd
Y1  - 2021/09/25/
JF  - Journal of Life Science and Biomedicine
A1  - IBADOV, Ravshan Aliyevich
A1  - ARIFJANOV, Anvar Shamkhatovich
A1  - IBRAGIMOV, Sardor Khamdamovich
A1  - KHAKIMOV, Begali Bobokulovich
VL  - 11
ID  - eprints570
ER  -